Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05000853
Other study ID # IDIBELL - EOM019/21
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date August 1, 2023

Study information

Verified date December 2022
Source Hospital Universitari de Bellvitge
Contact Josep Comin Colet, MD, PhD
Phone +34 932607078
Email jcomin@bellvitgehospital.cat
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of our study is to understand the biological pathways involved in the occurrence of IDy in patients with HF since ID is very common and supposes a negative impact in terms of clinical outcomes in these patients. In this context, a deeper understanding of the mechanisms involved in the development of ID in these patients and the impact on the altered biological pathways after iron replenishment will pave the way for an improvement and simplification of the preventive strategies in patients with HF.


Description:

The IRON-PATH II Project is a pre-clinical and clinical study designed as a multicenter, prospective, observational (non-interventional), investigator initiated study. The total number of patients to be recruited will be 210 (80 patients without ID and 130 patients with ID). Patients will be recruited during 12 months in 7 centers across Spain and Portugal and followed for a fixed period of 12 months. The primary objective of the clinical study is to define pathways associated with systemic and tissue ID in HF patients compared with non-ID HF patients and explore the change in the patterns of pathway activation/suppression after irons status normalization in ID patients with intravenous iron treatment using an integrative omics and systems biology approach including whole-genome analysis of gene expression (transcriptome), protein synthesis (proteomics) and metabolic characterization (metabolomics) from blood samples. Key secondary objectives will include changes in patient-reported outcomes (PROMs) such as QoL, patient-reported experience measures (PREMs), the occurrence of events, among others between those with and without ID. The aims of the pre-clinical study is to confirm previous findings of the IRONPATH I study and to explore in vitro interventions in cardiac cells models with iron deficiency.


Recruitment information / eligibility

Status Recruiting
Enrollment 210
Est. completion date August 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years old. - HF diagnosis according to European Society of Cardiology - LVEF=50% (systolic HF). - Patients receiving oral standard medication for chronic HF. - Iron status evaluated in the last 3 months. - Written informed consent. Exclusion Criteria: - Age<18 years old. - Intravenous or oral iron administration or under treatment with ESA (erythropoiesis-stimulating agents) in the previous 3 months. - Planned cardiac resynchronization therapy (CRT), revascularization and other major interventions including heart transplant or left ventricular assist device (LVAD) implantation in the next 3 months in patients with ID. - Planned uptitration of guideline-mandatory HF-modifying drugs in the next 3 months (except iron repletion) in patients with ID. - Moderate or severe anaemia (Hb<11 g/dL). - The patient is unable or unwilling to give the informed consent to participate. - Unstable patients with signs of fluid overload or low cardiac output at the moment of enrollment. - Life expectancy less than 1 year (excluding HF). - The patient is considered not to be an adequate candidate for this study according to the decision of the local investigator.

Study Design


Intervention

Drug:
Iron Carboxymaltose
Iron supplementation when is needed according to usual care

Locations

Country Name City State
Spain Hospital Universitari de Bellvtige Hospitalet de Llobregat Barcelona
Spain University Hospital Bellvitge L'Hospitalet de Llobregat Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitari de Bellvitge

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary To define pathways associated with iron deficiency (ID) in heart failure (HF) patients compared with non-ID HF patients Using an integrative omics and systems biology approach including whole-genome analysis of gene expression (transcriptome), protein synthesis (proteomics) and metabolic characterization (metabolomics) from blood samples. Twelve months after inclusion the patient
Secondary Functional Biomarkers (New York Heart Association [NYHA) Comparison between ID and non ID patients Twelve months after inclusion the patient
Secondary Improvement of self-care using a validated scale (European Heart Failure Self-Care Behavior Scale). Comparison between ID and non ID patients Twelve months after inclusion the patient
Secondary Patient-reported experience measures (PREMs) (IEXPAC) Comparison between ID and non ID patients Twelve months after inclusion the patient
Secondary Prognostic biomarkers (NT-proBNP) Comparison between ID and non ID patients Twelve months after inclusion the patient
Secondary Occurrence of events (all-cause death, HF-clinically related admissions, CV admissions) Comparison between ID and non ID patients Twelve months after inclusion the patient
Secondary Functional Biomarkers (6-minutes walking test [6MWT] distance) Comparison between ID and non ID patients Twelve months after inclusion the patient
Secondary Improvement of quality of life using a validated questionnaire (EUROQOL - 5D) Comparison between ID and non ID patients Twelve months after inclusion the patient
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy